Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease
globally and is estimated to affect one-third of the global population.
1
Cardiovascular disease (CVD) remains the leading cause of mortality for NAFLD because
it is closely associated with atherogenic dyslipidemia resulting in the formation
of coronary plaques.
- Toh J.Z.K.
- Pan X.H.
- Tay P.W.L.
- et al.
A meta-analysis on the global prevalence, risk factors and screening of coronary heart
disease in nonalcoholic fatty liver disease [e-pub ahead of print].
Clin Gastroenterol Hepatol. 2022; (Accessed July 1, 2022)https://doi.org/10.1016/j.cgh.2021.09.021
1
In a recent meta-analysis it was estimated that 44.6% have coronary heart disease
and concurrent structural heart changes can also occur resulting in diastolic dysfunction
in patients with NAFLD.
- Toh J.Z.K.
- Pan X.H.
- Tay P.W.L.
- et al.
A meta-analysis on the global prevalence, risk factors and screening of coronary heart
disease in nonalcoholic fatty liver disease [e-pub ahead of print].
Clin Gastroenterol Hepatol. 2022; (Accessed July 1, 2022)https://doi.org/10.1016/j.cgh.2021.09.021
1
,- Toh J.Z.K.
- Pan X.H.
- Tay P.W.L.
- et al.
A meta-analysis on the global prevalence, risk factors and screening of coronary heart
disease in nonalcoholic fatty liver disease [e-pub ahead of print].
Clin Gastroenterol Hepatol. 2022; (Accessed July 1, 2022)https://doi.org/10.1016/j.cgh.2021.09.021
2
Despite the significant cardiac burden in patients with NAFLD, predicting CVD mortality
in patients with NAFLD remains challenging. Traditional risk scoring systems including
Framingham Heart Score do not account for hepatic fibrosis that has been closely associated
with CVD events.
3
However, emerging evidence has shown the potential of noninvasive tests (NITs) in
predicting outcomes in NAFLD.
4
Higuchi et al. used magnetic resonance elastography to predict major adverse cardiovascular
events (MACE) in patients with NAFLD.
5
It remains to be seen if serological NITs are effective in predicting CVD disease
and mortality. Hence, we sought to examine the applicability of NITs including Fibrosis-4
Index (FIB-4), AST to Platelet Ratio Index (APRI) and NAFLD Fibrosis Score (NFS) to
predict CVD events and mortality in NAFLD.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- A meta-analysis on the global prevalence, risk factors and screening of coronary heart disease in nonalcoholic fatty liver disease [e-pub ahead of print].Clin Gastroenterol Hepatol. 2022; (Accessed July 1, 2022)https://doi.org/10.1016/j.cgh.2021.09.021
- Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis.Hepatol Int. 2022; 16: 269-281
- 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.J Am Coll Cardiol. 2019; 74: e177-e232
- Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease.Hepatol Res. 2022; 52: 497-507
- Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality.Aliment Pharmacol Ther. 2022; 55: 292-301
Article Info
Publication History
Published online: August 03, 2022
Accepted:
July 12,
2022
Received:
May 9,
2022
Identification
Copyright
© 2022 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
